Royal London Asset Management Ltd. Acquires 4,072 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

Royal London Asset Management Ltd. raised its holdings in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 0.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 486,243 shares of the medical equipment provider’s stock after purchasing an additional 4,072 shares during the quarter. Royal London Asset Management Ltd. owned 0.14% of Intuitive Surgical worth $164,039,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in ISRG. Catalyst Capital Advisors LLC lifted its position in shares of Intuitive Surgical by 34.2% during the third quarter. Catalyst Capital Advisors LLC now owns 259 shares of the medical equipment provider’s stock worth $76,000 after purchasing an additional 66 shares during the last quarter. Truepoint Inc. bought a new stake in shares of Intuitive Surgical in the third quarter valued at about $207,000. Johnson Investment Counsel Inc. raised its holdings in shares of Intuitive Surgical by 1.6% in the third quarter. Johnson Investment Counsel Inc. now owns 25,034 shares of the medical equipment provider’s stock valued at $7,317,000 after acquiring an additional 384 shares in the last quarter. Kestra Advisory Services LLC raised its holdings in shares of Intuitive Surgical by 4.6% in the third quarter. Kestra Advisory Services LLC now owns 12,910 shares of the medical equipment provider’s stock valued at $3,773,000 after acquiring an additional 563 shares in the last quarter. Finally, Concorde Asset Management LLC raised its holdings in shares of Intuitive Surgical by 31.3% in the third quarter. Concorde Asset Management LLC now owns 964 shares of the medical equipment provider’s stock valued at $282,000 after acquiring an additional 230 shares in the last quarter. 83.64% of the stock is currently owned by institutional investors.

Intuitive Surgical Stock Performance

Shares of NASDAQ ISRG traded up $2.88 during mid-day trading on Friday, reaching $425.78. 940,996 shares of the company’s stock were exchanged, compared to its average volume of 1,163,301. The firm has a market capitalization of $151.02 billion, a price-to-earnings ratio of 76.86, a PEG ratio of 5.50 and a beta of 1.39. Intuitive Surgical, Inc. has a 52-week low of $254.85 and a 52-week high of $428.86. The company’s 50-day moving average is $392.70 and its 200-day moving average is $374.43.

Intuitive Surgical (NASDAQ:ISRG) last released its quarterly earnings results on Thursday, April 18th. The medical equipment provider reported $1.50 earnings per share for the quarter, topping analysts’ consensus estimates of $1.40 by $0.10. The business had revenue of $1.89 billion during the quarter, compared to analysts’ expectations of $1.87 billion. Intuitive Surgical had a return on equity of 12.91% and a net margin of 27.16%. The company’s revenue was up 11.5% compared to the same quarter last year. During the same period in the prior year, the business posted $1.00 EPS. As a group, equities analysts predict that Intuitive Surgical, Inc. will post 4.8 earnings per share for the current fiscal year.

Insider Activity at Intuitive Surgical

In other Intuitive Surgical news, EVP Robert Desantis sold 1,498 shares of the stock in a transaction dated Friday, April 26th. The stock was sold at an average price of $369.92, for a total value of $554,140.16. Following the sale, the executive vice president now owns 5,507 shares of the company’s stock, valued at approximately $2,037,149.44. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, EVP Robert Desantis sold 1,498 shares of the firm’s stock in a transaction dated Friday, April 26th. The stock was sold at an average price of $369.92, for a total transaction of $554,140.16. Following the sale, the executive vice president now owns 5,507 shares of the company’s stock, valued at approximately $2,037,149.44. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Craig H. Barratt sold 1,400 shares of the firm’s stock in a transaction dated Wednesday, June 12th. The stock was sold at an average price of $421.06, for a total value of $589,484.00. The disclosure for this sale can be found here. Insiders sold 17,956 shares of company stock worth $6,927,011 in the last three months. 0.90% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several analysts recently weighed in on the company. Robert W. Baird decreased their price objective on Intuitive Surgical from $440.00 to $436.00 and set an “outperform” rating for the company in a report on Friday, April 19th. Stifel Nicolaus boosted their target price on shares of Intuitive Surgical from $420.00 to $430.00 and gave the stock a “buy” rating in a report on Monday, April 8th. Citigroup boosted their target price on shares of Intuitive Surgical from $428.00 to $462.00 and gave the stock a “buy” rating in a report on Wednesday, April 3rd. StockNews.com downgraded shares of Intuitive Surgical from a “buy” rating to a “hold” rating in a report on Thursday, February 29th. Finally, BTIG Research boosted their target price on shares of Intuitive Surgical from $412.00 to $421.00 and gave the stock a “buy” rating in a report on Friday, April 19th. Five equities research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $403.67.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.